Human Insulin Market: Information by Type (Traditional Human Insulin (Premixed Traditional, Intermediate Acting and Short-Acting), Modern Human Insulin (Premixed Modern, Long-Acting and Rapid Acting) and Brand (Lantus, Novorapid, Humalog, Novomix, Levemir, Apidar, Humulin and Insuman)) and Region (Americas, Europe, Asia-Pacific and Middle East & Africa) - Global Forecast till 2027
ID: MRFR/Pharma/0445-CR | February 2021 | Region: Global | 117 pages
Global Human Insulin Market is expected to grow at CAGR of 12.10% to reach USD 90,812.40 Million till 2025. Human insulin in the report refers to synthetic insulin manufactured in laboratories by increasing insulin protein with the help of e. coli bacteria. Human insulin can be administered orally or through insulin infusion devices. Some conventional insulin infusion devices are syringes, injection pens, and insulin pumps. These devices are used to deliver insulin on time and regularly.
Increasing prevalence of diabetes, rising obesity endemic, rise in geriatric population, and increasing awareness among people about diabetic care and technological advancement in delivery devices of insulin are some of the factors influencing the growth of the human insulin market. However, strict regulatory requirements for approval of insulin and high cost of insulin analog inhibit the growth of the human insulin market.
Market Dynamics
The increasing affordability of human insulin is one of the key factors driving the human insulin market. In May 2019, Eli Lilly and Company launched Insulin Lispro Injection for people who use Lilly's rapid-acting insulin and need a lower-cost option. Insulin Lispro Injection has a 50% lower price than its identical medicine, Humalog U-100 (insulin lispro injection).
Increasing diabetic population is also strongly impacting the growth of the market. Diabetes is a chronic and non-communicable disease, and its global prevalence is rising enormously. Nowadays, it is one of the leading causes of death and has an increased risk of developing several serious health problems. It is the primary cause of cardiovascular diseases, kidney diseases, eye disorders, and strokes.
As per 2017, National Diabetes Statistic Report suggested by the Centers for Disease Control and Prevention, more than 100 million people in the US have diabetes or prediabetes.
Global Human Insulin Market Revenue, by Traditional Human Insulin, 2018 (%) 
Sources: MRFR Analysis
Segmentation
Based on type, the global human insulin market has been segmented into traditional human insulin and modern human insulin. Traditional human insulin segment includes premixed traditional, intermediate-acting, and short-acting. Modern human insulin segment includes premixed modern, long-acting, and rapid-acting. Modern human insulin was the leading segment in 2018. Modern human insulin, also known as analog insulin, is prescribed by physicians for the treatment of diabetes. It is the customized form of traditional human insulin and provides effective results in comparison to traditional human insulin.
The global human insulin market, by brand, has been segmented into Lantus, Novorapid, Humalog, Novomix, Levemir, Apidar, Humulin, and Insuman. Lantus is a long-acting human insulin analog, and it is available in more than 120 countries. Among all the brands, Lantus commands the largest share in the human insulin market. Apidra is a rapid acting human insulin analog. Also, Apidra and Levemir are the fastest growing brand in the human insulin market. Moreover, there are various drugs in the pipeline, which would have a positive impact on the growth of the market in the coming years.
Global Human Insulin Market Share, by Region, 2018 (%) 
Sources: MRFR Analysis
Regional Analysis
The global human insulin market has been categorized as the Americas, Europe, Asia-Pacific, and Middle East & Africa.
The Americas dominate the global human insulin market, owing to the growing old age population, increasing healthcare awareness, rising prevalence of diabetes, improvement in reimbursement policies, and increasing clinical trials driving the growth of human insulin.
The European Human Insulin market has been segmented into Western Europe and Eastern Europe. In 2018, Europe stood second in the global Human Insulin market. Increasing focus on the treatment of diabetes and rising clinical trials by market players will support the growth of Europe Human Insulin market. For instance, a France-based firm, Adocia received positive topline pharmacodynamic and safety results from the first Phase 1 study of ADO09. ADO09 is intended to improve postprandial glucose control and long-term outcomes for people requiring prandial insulin treatment.
Asia-Pacific is expected to register the highest CAGR during the forecast period. Companies are introducing new advanced products in this region, which is boosting Asia-Pacific human insulin market. In March 2018, Biocon Ltd and Mylan NV received approval for biosimilar insulin glargine Semglee 100 IU/mL 3 mL prefilled pen from the Therapeutic Goods Administration (TGA) Australia.
On the other hand, the Middle East & Africa holds the least share in the global human insulin market due to the low economic development, especially within the African region.
Key Players
The prominent players in the global human insulin market are ADOCIA, MERCK & CO., INC., Julphar, Pfizer Inc., Bristol-Myers Squibb Company, GLAXOSMITHKLINE PLC, SANOFI, Oramed, Novo Nordisk India Pvt. Ltd, Eli Lilly and Company, BIOCON, and Tonghua Dongbao Pharmaceutical Co., Ltd.
Some of the key strategies followed by the players operating in the global human insulin market were innovation, product development, acquisition, and expansion.
- In August 2018, Novo Nordisk acquired all the shares of Ziylo. Through this acquisition, Novo Nordisk gained full rights to Ziylo's glucose binding molecule platform to develop glucose responsive insulins (GRIs). This is a critical strategic area for Novo Nordisk in its effort to develop this next generation of insulin, which would lead to safer and more effective insulin therapy.
- In April 2015, Biocon announced that its Insulin Glargine has been approved by COFEPRIS, the Mexican health authority, through its partner PiSAFarmaceutica (PiSA) and has strengthened its position in Mexico.
Market Segmentation
Global Human Insulin Market, by Type
- Traditional Human Insulin
- Premixed Traditional
- Intermediate Acting
- Short-Acting
- Modern Human Insulin
- Premixed Modern
- Long-Acting
- Rapid Acting
Global Human Insulin Market, by Brand
- Lantus
- Novorapid
- Humalog
- Novomix
- Levemir
- Apidar
- Humulin
- Insurance
Global Human Insulin Market, by Region
- Americas
- North America
- US
- Canada
- Latin America
- North America
- Europe
- Western Europe
- Germany
- France
- Italy
- UK
- Spain
- Rest of Western Europe
- Eastern Europe
- Western Europe
- Asia-Pacific
- Japan
- China
- Australia
- India
- South Korea
- Rest of Asia-Pacific
- Middle East & Africa
- Middle East
- Africa
Intended Audience
- Pharmaceuticals manufacturers and suppliers
- Medical research laboratories
- Research and development (R&D) companies
- Market research and consulting service providers
- Potential investors
Report Scope:
| Report Attribute/Metric | Details |
|---|---|
| Market Size |
|
| CAGR | 12.10% (2019-2025) |
| Base Year | 2019 |
| Forecast Period | 2020-2027 |
| Historical Data | 2018 |
| Forecast Units | Value (USD Million) |
| Report Coverage | Revenue Forecast, Competitive Landscape, Growth Factors, and Trends |
| Segments Covered | Type, Modern Human Insulin and Brand |
| Geographies Covered | North America, Europe, Asia-Pacific, and Rest of the World (RoW) |
| Key Vendors | ADOCIA, MERCK & CO., INC., Julphar, Pfizer Inc., Bristol-Myers Squibb Company, GLAXOSMITHKLINE PLC, SANOFI, Oramed, Novo Nordisk India Pvt. Ltd, Eli Lilly and Company, BIOCON, and Tonghua Dongbao Pharmaceutical Co., Ltd. |
| Key Market Opportunities | increasing affordability of human insulin |
| Key Market Drivers |
|
Frequently Asked Questions (FAQ) :
Global Human Insulin Market is expected to accumulate revenues at a CAGR of 12.1% from 2020 to 2027.
Global Human Insulin Market is driven by the large prevalence of diabetes mellitus.
The large geriatric populace affected by diabetes and diabetes management are two of the secondary drivers which can fuel the Global Human Insulin Market.
The Americas holds the largest share of the Global Human Insulin Market.
Europe holds the second-largest share of the Global Human Insulin Market owing to heavy funds in research of diabetes.
Oramed Pharmaceuticals, Inc., ADOCIA, Julphar, Novo Nordisk A/S, Bristol-Myers Squibb Company, Tonghua Dongbao Pharmaceuticals Co., Ltd., Biocon Ltd, Merck & Co, GlaxoSmithKline, Sanofi, and Pfizer, Inc. are major players of the Global Human Insulin Market.
1 Report Prologue
2 Market Introduction
2.1 Definition
2.2 Scope of the Study
2.2.1 Research Objective
2.2.2 Assumptions
2.2.3 Limitations
3 Research Methodology
3.1 Introduction
3.2 Primary Research
3.3 Secondary Research
3.4 Market Size Estimation
4 Market Dynamics
4.1 Drivers
4.2 Restraints
4.3 Opportunities
4.4 Macroeconomic Indicators
4.5 Trends & Assessment
5 Market Factor Analysis
5.1 Porter’s Five Forces Analysis
5.1.1 Bargaining Power of Suppliers
5.1.2 Bargaining Power of Buyers
5.1.3 Threat of New Entrants
5.1.4 Threat of Substitutes
5.1.5 Intensity of Rivalry
5.2 Value Chain Analysis
5.3 Investment Opportunities
6 Human Insulin Market, by Type
6.1 Introduction
6.2 Traditional Human Insulin
6.2.1 Premixed Traditional
Market Estimates & Forecast, by Region, 2020–2027
Market Estimates & Forecast, by Country, 2020–2027
6.2.2 Intermediate Acting
Market Estimates & Forecast, by Region, 2020–2027
Market Estimates & Forecast, by Country, 2020–2027
6.2.3 Short Acting
Market Estimates & Forecast, by Region, 2020–2027
Market Estimates & Forecast, by Country, 2020–2027
6.3 Modern Human Insulin
6.3.1 Premixed Modern
Market Estimates & Forecast, by Region, 2020–2027
Market Estimates & Forecast, by Country, 2020–2027
6.3.2 Long Acting
Market Estimates & Forecast, by Region, 2020–2027
Market Estimates & Forecast, by Country, 2020–2027
6.3.3 Rapid Acting
Market Estimates & Forecast, by Region, 2020–2027
Market Estimates & Forecast, by Country, 2020–2027
7 Human Insulin Market, by Brand
7.1 Introduction
7.2 Lantus
Market Estimates & Forecast, by Region, 2020–2027
Market Estimates & Forecast, by Country, 2020–2027
7.3 Novorapid
Market Estimates & Forecast, by Region, 2020–2027
Market Estimates & Forecast, by Country, 2020–2027
7.4 Humalog
Market Estimates & Forecast, by Region, 2020–2027
Market Estimates & Forecast, by Country, 2020–2027
7.5 Novomix
Market Estimates & Forecast, by Region, 2020–2027
Market Estimates & Forecast, by Country, 2020–2027
7.6 Levemir
Market Estimates & Forecast, by Region, 2020–2027
Market Estimates & Forecast, by Country, 2020–2027
7.7 Apidar
Market Estimates & Forecast, by Region, 2020–2027
Market Estimates & Forecast, by Country, 2020–2027
7.8 Humulin
Market Estimates & Forecast, by Region, 2020–2027
Market Estimates & Forecast, by Country, 2020–2027
7.9 Insuman
Market Estimates & Forecast, by Region, 2020–2027
Market Estimates & Forecast, by Country, 2020–2027
8 Global Human Insulin Market, by Region
8.1 Introduction
8.2 Americas
Human Insulin Market, by Type
Human Insulin Market, by Brand
8.2.1 North America
Human Insulin Market, by Type
Human Insulin Market, by Brand
8.2.1.1 US
Human Insulin Market, by Type
Human Insulin Market, by Brand
8.2.1.2 Canada
Human Insulin Market, by Type
Human Insulin Market, by Brand
8.2.2 South America
Human Insulin Market, by Type
Human Insulin Market, by Brand
8.3 Europe
Human Insulin Market, by Type
Human Insulin Market, by Brand
8.3.1 Western Europe
Human Insulin Market, by Type
Human Insulin Market, by Brand
8.3.1.1 Germany
Human Insulin Market, by Type
Human Insulin Market, by Brand
8.3.1.2 France
Human Insulin Market, by Type
Human Insulin Market, by Brand
8.3.1.3 Italy
Human Insulin Market, by Type
Human Insulin Market, by Brand
8.3.1.4 Spain
Human Insulin Market, by Type
Human Insulin Market, by Brand
8.3.1.5 UK
Human Insulin Market, by Type
Human Insulin Market, by Brand
8.3.1.6 Rest of Western Europe
Human Insulin Market, by Type
Human Insulin Market, by Brand
8.3.2 Eastern Europe
Human Insulin Market, by Type
Human Insulin Market, by Brand
8.4 Asia-Pacific
Human Insulin Market, by Type
Human Insulin Market, by Brand
8.4.1 Japan
Human Insulin Market, by Type
Human Insulin Market, by Brand
8.4.2 China
Human Insulin Market, by Type
Human Insulin Market, by Brand
8.4.3 India
Human Insulin Market, by Type
Human Insulin Market, by Brand
8.4.4 Australia
Human Insulin Market, by Type
Human Insulin Market, by Brand
8.4.5 South Korea
Human Insulin Market, by Type
Human Insulin Market, by Brand
8.4.6 Rest of Asia-Pacific
Human Insulin Market, by Type
Human Insulin Market, by Brand
8.5 Middle East & Africa
Human Insulin Market, by Type
Human Insulin Market, by Brand
8.5.1 Middle East
Human Insulin Market, by Type
Human Insulin Market, by Brand
8.5.2 Africa
Human Insulin Market, by Type
Human Insulin Market, by Brand
9 Company Landscape
9.1 Introduction
9.2 Market Share Analysis
9.3 Key Development & Strategies
10 Company Profiles
10.1 ADOCIA
10.1.1 Company Overview
10.1.2 Product Overview
10.1.3 Financials Overview
10.1.4 Key Developments
10.1.5 SWOT Analysis
10.2 MERCK & CO., INC.
10.2.1 Company Overview
10.2.2 Product Overview
10.2.3 Financial Overview
10.2.4 Key Developments
10.2.5 SWOT Analysis
10.3 Julphar
10.3.1 Company Overview
10.3.2 Product Overview
10.3.3 Financial Overview
10.3.4 Key Development
10.3.5 SWOT Analysis
10.4 Pfizer Inc.
10.4.1 Company Overview
10.4.2 Product Overview
10.4.3 Financial Overview
10.4.4 Key Development
10.4.5 SWOT Analysis
10.5 Bristol-Myers Squibb Company
10.5.1 Company Overview
10.5.2 Product Overview
10.5.3 Financial overview
10.5.4 Key Developments
10.5.5 SWOT Analysis
10.6 GLAXOSMITHKLINE PLC
10.6.1 Company Overview
10.6.2 Product Overview
10.6.3 Financial Overview
10.6.4 Key Developments
10.6.5 SWOT Analysis
10.7 SANOFI
10.7.1 Overview
10.7.2 Product Overview
10.7.3 Financials
10.7.4 Key Developments
10.7.5 SWOT Analysis
10.8 Oramed
10.8.1 Overview
10.8.2 Product Overview
10.8.3 Financials
10.8.4 Key Developments
10.8.5 SWOT Analysis
10.9 Novo Nordisk India Pvt. Ltd
10.9.1 Overview
10.9.2 Product Overview
10.9.3 Financials
10.9.4 Key Developments
10.9.5 SWOT Analysis
10.10 Eli Lilly and Company
10.10.1 Overview
10.10.2 Product Overview
10.10.3 Financials
10.10.4 Key Developments
10.10.5 SWOT Analysis
10.11 BIOCON
10.11.1 Overview
10.11.2 Product Overview
10.11.3 Financials
10.11.4 Key Developments
10.11.5 SWOT Analysis
10.12 Tonghua Dongbao Pharmaceutical Co., Ltd
10.12.1 Overview
10.12.2 Product Overview
10.12.3 Financials
10.12.4 Key Developments
10.12.5 SWOT Analysis
10.13 Others
11 MRFR Conclusion
11.1 Key Findings
11.1.1 From CEO’s Viewpoint
11.1.2 Unmet Needs of the Market
11.2 Key Companies to Watch
11.3 Predictions for the global Human Insulin market
12 Appendix
13 LIST OF TABLES
Table 1 Human Insulin Market Synopsis, 2020–2027
Table 2 Human Insulin Market Estimates and Forecast, 2020–2027 (USD Million)
Table 3 Global Human Insulin Market, by Region, 2020–2027 (USD Million)
Table 4 Global Human Insulin Market, by Type, 2020–2027 (USD Million)
Table 5 Global Human Insulin Market, by Brand, 2020–2027 (USD Million)
Table 6 North America: Human Insulin Market, by Type, 2020–2027 (USD Million)
Table 7 North America: Human Insulin Market, by Brand, 2020–2027 (USD Million)
Table 8 US: Human Insulin Market, by Type, 2020–2027 (USD Million)
Table 9 US: Human Insulin Market, by Brand, 2020–2027 (USD Million)
Table 10 Canada: Human Insulin Market, by Type, 2020–2027 (USD Million)
Table 11 Canada: Human Insulin Market, by Brand, 2020–2027 (USD Million)
Table 12 South America: Human Insulin Market, by Type, 2020–2027 (USD Million)
Table 13 South America: Human Insulin Market, by Brand, 2020–2027 (USD Million)
Table 14 Europe: Human Insulin Market, by Type, 2020–2027 (USD Million)
Table 15 Europe: Human Insulin Market, by Brand, 2020–2027 (USD Million)
Table 16 Western Europe: Human Insulin Market, by Type, 2020–2027 (USD Million)
Table 17 Western Europe: Human Insulin Market, by Brand, 2020–2027 (USD Million)
Table 18 Eastern Europe: Human Insulin Market, by Type, 2020–2027 (USD Million)
Table 19 Eastern Europe: Human Insulin Market, by Brand, 2020–2027 (USD Million)
Table 20 Asia-Pacific: Human Insulin Market, by Type, 2020–2027 (USD Million)
Table 21 Asia-Pacific: Human Insulin Market, by Brand, 2020–2027 (USD Million)
Table 22 Middle East & Africa: Human Insulin Market, by Type, 2020–2027 (USD Million)
Table 23 Middle East & Africa: Human Insulin Market, by Brand, 2020–2027 (USD Million)
14 LIST OF FIGURES
Figure 1 Research Process
Figure 2 Segmentation for Global Human Insulin Market
Figure 3 Market Dynamics for Global Human Insulin Market
Figure 4 Human Insulin Market Share, by Type, 2020
Figure 5 Human Insulin Market Share, by Brand, 2020
Figure 6 Human Insulin Market Share, by Region, 2020
Figure 7 North America: Human Insulin Market Share, by Country, 2020
Figure 8 Europe: Human Insulin Market Share, by Country, 2020
Figure 9 Asia-Pacific: Human Insulin Market Share, by Country, 2020
Figure 10 Middle East & Africa: Human Insulin Market Share, by Region, 2020
Figure 11 Human Insulin Market: Company Share Analysis, 2020 (%)
Figure 12 ADOCIA: Key Financials
Figure 13 ADOCIA: Segmental Revenue
Figure 14 ADOCIA: Geographical Revenue
Figure 15 MERCK & CO., INC.: Key Financials
Figure 16 MERCK & CO., INC.: Segmental Revenue
Figure 17 MERCK & CO., INC.: Geographical Revenue
Figure 18 Julphar: Key Financials
Figure 19 Julphar: Segmental Revenue
Figure 20 Julphar: Geographical Revenue
Figure 21 Pfizer Inc.: Key Financials
Figure 22 Pfizer Inc.: Segmental Revenue
Figure 23 Pfizer Inc.: Geographical Revenue
Figure 24 Bristol-Myers Squibb Company: Key Financials
Figure 25 Bristol-Myers Squibb Company: Segmental Revenue
Figure 26 Bristol-Myers Squibb Company: Geographical Revenue
Figure 27 GLAXOSMITHKLINE PLC: Key Financials
Figure 28 GLAXOSMITHKLINE PLC: Segmental Revenue
Figure 29 GLAXOSMITHKLINE PLC: Geographical Revenue
Figure 30 Oramed: Key Financials
Figure 31 Oramed: Segmental Revenue
Figure 32 Oramed: Geographical Revenue
Figure 33 Novo Nordisk India Pvt Ltd: Key Financials
Figure 34 Novo Nordisk India Pvt Ltd: Segmental Revenue
Figure 35 Novo Nordisk India Pvt Ltd: Geographical Revenue
Figure 36 Eli Lilly and Company: Key Financials
Figure 37 Eli Lilly and Company: Segmental Revenue
Figure 38 Eli Lilly and Company: Geographical Revenue
Figure 39 SANOFI: Key Financials
Figure 40 SANOFI: Segmental Revenue
Figure 41 SANOFI: Geographical Revenue
Figure 42 BIOCON: Key Financials
Figure 43 BIOCON: Segmental Revenue
Figure 44 BIOCON: Geographical Revenue
Figure 45 Tonghua Dongbao Pharmaceutical Co., Ltd.: Key Financials
Figure 46 Tonghua Dongbao Pharmaceutical Co., Ltd.: Segmental Revenue
Figure 47 Tonghua Dongbao Pharmaceutical Co., Ltd.: Geographical Revenue